QualityStocks would like to highlight Senesco Technologies, Inc. (NYSE: SNT), a development stage biotechnology company that develops products and technologies to treat programmed cell death diseases in humans. The company's therapeutic candidate, SNS01-T is in Phase Ib/IIa clinical study for treatment of multiple myeloma. It also develops and licenses gene technologies to enhance the productivity of fruits, flowers, vegetables, and agronomic crops through the control of cell death in plants.
In the company’s news yesterday,
Senesco Technologies announced that the combination of bortezomib – the active component of VELCADE marketed by Millenium: The Takeda Oncology Company – and SNS01-T, which is the subject of Senesco’s ongoing multiple myeloma clinical study, results in substantially better performance in mouse xenograft models than either treatment by itself.
SNS01-T enhances bortezomib’s ability to inhibit tumor growth in the mouse model and could potentially be a means of lowering the dose and reducing the severity of treatment-related side effects of bortezomib. As treatment increasingly involves combination therapy, it is important for SNS01-T to work well when added to current multiple myeloma drugs.
In the clinical study, mice implanted in the flank with human myeloma RPMI 8226 cells were treated with SNS01-T (0.375 mg/Kg IV) or one of two different dose levels of bortezomib (0.2, 0.5 mg/Kg IP), alone or combined with SNS01-T. SNS01-T and bortezomib were administered twice a week for six weeks. The study employed an active nanoparticle as the control. SNS01-T monotherapy achieved 59 percent tumor growth inhibition, exceeding that of bortezomib by itself at either the 0.2 mg/kg dose (22 percent inhibition) or at 0.5 mg/kg (39 percent inhibition). However, the combination of SNS01-T with 0.5 mg/kg of bortezomib resulted in 89 percent tumor inhibition.
Senesco recently reported that SNS01-T combined with lenalidomide, which is the active component of leading multiple myeloma treatment REVLIMID marketed by Celgene Corporation, strongly inhibited human multiple myeloma tumor growth during six weeks of treatment in mice, resulting in no regrowth of tumors after an additional eight weeks without further treatment.
Senesco Technologies is a leader in eIF5A technology and is presently running a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis (cell death) by modulating eukaryotic, translation, initiation Factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. The company has already partnered with leading-edge companies that are engaged in agricultural biotechnology, and Senesco is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.